Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Many congratulations to Dr Onima Chowdhury, awarded a £250,000 grant by the Medical Research Council

Dr Onima ChowdhuryDr Onima ChowdhuryMyelodysplastic syndromes (MDS) are malignant haematopoietic stem cell diseases that can lead to anaemia, bleeding and life threatening infections, with a significant number of patients progressing to acute leukaemia. Difficult to treat and often fatal, it affects around 50 per 100,000 in those over 60 years old, resulting in around 5000 patients in the UK. This makes it one of the most common haematological malignancies in the elderly.

However, patients referred to specialist services with suspected MDS are often unable to receive a clear diagnosis, leading to a delay in the delivery of available treatments. Current diagnostic methods are based on a reduction in the number of mature blood cells and the abnormal morphology of bone marrow cells. However, these findings are not specific for MDS.

To overcome these issues, Dr Chowdhury will collaborate with the group of Prof Adam Mead to explore the application of single cell genomics for the diagnosis of MDS. Dr Chowdhury will examine patient samples using this technique, alongside traditional diagnostic methods.

“I hope that this research can help improve the current diagnostic tests for MDS and capture more of the patients we are missing. This is essential if we are to provide the best treatments as early as possible for patients” Said Dr Chowdhury “More broadly, this work will provide proof of principle for the application of single cell genomics in routine clinical cancer diagnostics.”

Dr Chowdhury has been a Consultant Haematologist in the Oxford University Hospitals since 2018. She studied medicine at the University of Cambridge and University of Oxford, where she also completed her PhD in 2014.

The Medical Research Council Clinical Academic Research Partnership scheme allows NHS consultants with a PhD or MD to participate in collaborative high-quality research partnerships with established leading biomedical researchers.

Similar stories

DNA breakthrough could help identify why some people are more affected by Covid-19

Scientists from the MRC Weatherall Institute of Molecular Medicine have developed a method that allows them to see, with far greater accuracy, how DNA forms large scale structures within a cell nucleus.

New clinical trial for patients affected by blood cancer

Radcliffe Department of Medicine's Professor Adam Mead is leading PROMise, a new clinical trial offering a novel treatment option for patients with a type of blood cancer called myelofibrosis.

Immune cells imperfect at distinguishing friend from foe

When it comes to distinguishing a healthy cell from an infected one that needs to be destroyed, the immune system’s killer T cells sometimes make mistakes. This discovery, described today in the journal eLife, upends a long-held belief among scientists that T cells were nearly perfect at discriminating friend from foe. The results may point to new ways to treat autoimmune diseases that cause the immune system to attack the body, or lead to improvements in cutting-edge cancer treatments.

Professor Graham Ogg elected Academy of Medical Sciences Fellow

Fellows are selected for their exceptional contributions to the advancement of medical science through innovative research discoveries and translating scientific developments into benefits for patients and the wider society.

New funding for early diagnosis research using platelets

Dr Bethan Psaila and her team will investigate the potential of circulating blood platelets for early detection of a range of cancer types.